Funding Backs Next-Generation Genomic Measurement Tools
Countable Labs raises $26 million to accelerate the development and commercial rollout of its single-molecule PCR technology. The round was led by ARCH Venture Partners, with participation from F-Prime Capital and Primer Ventures. The raise strengthens its capacity to deliver genomic measurement tools.
The business developed Countable PCR, a platform that offers higher sensitivity and clarity than digital PCR. The method removes the need for Poisson correction. It also avoids standard curves. The approach aims to give laboratories more confidence when measuring rare biological signals.
The company said this clarity helps teams working in genomics make better decisions faster. Fit-for-purpose solutions that address cell and gene therapy, minimal residual disease testing, biomarker validation, and vaccine quality control are supported by the new capital.
These markets are in greater need of accuracy, and in this regard, the company views Countable PCR as a practical solution for labs looking for accuracy that accommodates a wider dynamic range and simpler workflows.
Countable Labs hired a new VP of Global Sales for their commercial rollout. The addition of the VP shows that the company is dedicated to increasing their reach in several major markets. The new hire has substantial experience in sales of tools for life sciences.
Countable PCR Targets Critical Genomic Applications
Countable PCR is designed for sensitive applications where small biological signals matter. Its single-molecule approach captures information that traditional PCR and digital PCR miss. The company said this level of detail is essential for understanding genetic markers, detecting rare events, and validating biomarkers linked to disease.
The technology includes a 10-colour capability. This enables a wide range of multiplexing options that support complex genomic studies. The platform is purpose-built for research and industrial settings. It aims to help laboratories detect fusions, track markers of genome integrity, and measure inherited patterns across complex samples.
The company said these abilities help teams uncover insights that would remain hidden using standard tools. The method uses molecular linkage to understand genetic patterns. This capability allows scientists to see how different regions of the genome relate to each other.
That information strengthens research across oncology, diagnostics, and therapy development. The platform aims to open new possibilities in genomic science, providing the clarity needed for high-stakes decisions. Countable Labs believes 2026 will be a decisive year for the technology.
Early studies showed strong performance in clinical samples. These results validated the robustness of the platform. The company now prepares to scale production and introduce category-specific products for laboratories that demand precision and ease of use.
Funding Supports Global Expansion and Product Strategy
Countable Labs scales precision genomic tools for worldwide adoption. Source: Created by Ventureburn
The company plans to use its new funding to expand commercial operations worldwide. It aims to ensure that laboratories seeking precision genomic tools can access Countable PCR without friction. The leadership team said that many segments still rely on digital PCR or next-generation sequencing.
These methods offer value but can introduce ambiguity. Countable Labs aims to remove this ambiguity by providing a simple and sensitive alternative. The investment from ARCH Venture Partners reflects strong confidence in the platform’s technical foundation. The firm said PCR requires new solutions that offer speed, accuracy, and lower cost.
It added that Countable Labs reimagined PCR in a way that could support high-volume testing across many sectors. This includes translational science, industrial testing, and advanced research. F-Prime Capital highlighted the potential for broad adoption.
The firm said that making rare event detection widely accessible will support global health, oncology, and therapy manufacturing. It added that Countable PCR can replace existing methods in areas where cost, complexity, or ambiguity limit progress.
More News: Secretome Therapeutics Raises $30M Series A for Cardiac Cell Therapy Expansion
Positioning for Leadership in Genomic Measurement
Countable Labs positions itself as a company redefining how biology is measured. It offers tools that deliver ten times the sensitivity of standard PCR. It also provides quantitative accuracy beyond what digital PCR and next-generation sequencing currently achieve.
The company believes these advantages will help laboratories detect rare genomic targets with new confidence. The business plans to grow its presence across oncology, cell and gene therapy, molecular diagnostics, and industrial testing.
Each segment requires high analytical performance. According to the company, its platform can fulfil these desires with an ease of access that comes naturally with straightforward technology. The company founders said that a simple, sensitive and yet affordable platform capable of enabling large-scale testing will be central to the future of genomic screening.
Countable PCR offers a perfect fit as a sensitive, yet straightforward, platform. There is clear demand in the market, including in the labs market, for a method that enables detection but does not depend on the use of cumbersome or expensive platforms.
This funding will also facilitate increased development within the team to create and launch a raft of specialised products targeting use-specific applications that will cement Countable PCR’s position as a go-to choice for ultra-sensitive measurement.
To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.
